Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial

G. Hasenfuß, C. Hayward, D. Burkhoff, FE. Silvestry, S. McKenzie, F. Gustafsson, F. Malek, J. Van der Heyden, I. Lang, MC. Petrie, JG. Cleland, M. Leon, DM. Kaye, . ,

. 2016 ; 387 (10025) : 1298-304.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze I, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16019988
E-zdroje Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

Odkazy

PubMed 27025436
DOI 10.1016/s0140-6736(16)00704-2
Knihovny.cz E-zdroje

BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) is a common, globally recognised, form of heart failure for which no treatment has yet been shown to improve symptoms or prognosis. The pathophysiology of HFPEF is complex but characterised by increased left atrial pressure, especially during exertion, which might be a key therapeutic target. The rationale for the present study was that a mechanical approach to reducing left atrial pressure might be effective in HFPEF. METHODS: The REDUCe Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF) study was an open-label, single-arm, phase 1 study designed to assess the performance and safety of a transcatheter interatrial shunt device (IASD, Corvia Medical, Tewkesbury, MA, USA) in patients older than 40 years of age with symptoms of HFPEF despite pharmacological therapy, left ventricular ejection fraction higher than 40%, and a raised pulmonary capillary wedge pressure at rest (>15 mm Hg) or during exercise (>25 mm Hg). The study was done at 21 centres (all departments of cardiology in the UK, Netherlands, Belgium, France, Germany, Austria, Denmark, Australia, and New Zealand). The co-primary endpoints were the safety and performance of the IASD at 6 months, together with measures of clinical efficacy, including functional capacity and clinical status, analysed per protocol. This study is registered with ClinicalTrials.gov, number NCT01913613. FINDINGS: Between Feb 8, 2014, and June 10, 2015, 68 eligible patients were entered into the study. IASD placement was successful in 64 patients and seemed to be safe and well tolerated; no patient had a peri-procedural or major adverse cardiac or cerebrovascular event or need for cardiac surgical intervention for device-related complications during 6 months of follow-up. At 6 months, 31 (52%) of 60 patients had a reduction in pulmonary capillary wedge pressure at rest, 34 (58%) of 59 had a lower pulmonary capillary wedge pressure during exertion, and 23 (39%) of 59 fulfilled both these criteria. Mean exercise pulmonary capillary wedge pressure was lower at 6 months than at baseline, both at 20 watts workload (mean 32 mm Hg [SD 8] at baseline vs 29 mm Hg [9] at 6 months, p=0·0124) and at peak exercise (34 mm Hg [8] vs 32 [8], p=0·0255), despite increased mean exercise duration (baseline vs 6 months: 7·3 min [SD 3·1] vs 8·2 min [3·4], p=0·03). Sustained device patency at 6 months was confirmed by left-to-right shunting (pulmonary/systemic flow ratio: 1·06 [SD 0·32] at baseline vs 1·27 [0·20] at 6 months, p=0·0004). INTERPRETATION: Implantation of an interatrial shunt device is feasible, seems to be safe, reduces left atrial pressure during exercise, and could be a new strategy for the management of HFPEF. The effectiveness of IASD compared with existing treatment for patients with HFPEF requires validation in a randomised controlled trial. FUNDING: Corvia Medical Inc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16019988
003      
CZ-PrNML
005      
20160727120357.0
007      
ta
008      
160722s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(16)00704-2 $2 doi
024    7_
$a 10.1016/S0140-6736(16)00704-2 $2 doi
035    __
$a (PubMed)27025436
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hasenfuß, Gerd $u Heart Centre, Georg-August Universität, Gottingen, Germany.
245    12
$a A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial / $c G. Hasenfuß, C. Hayward, D. Burkhoff, FE. Silvestry, S. McKenzie, F. Gustafsson, F. Malek, J. Van der Heyden, I. Lang, MC. Petrie, JG. Cleland, M. Leon, DM. Kaye, . ,
520    9_
$a BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) is a common, globally recognised, form of heart failure for which no treatment has yet been shown to improve symptoms or prognosis. The pathophysiology of HFPEF is complex but characterised by increased left atrial pressure, especially during exertion, which might be a key therapeutic target. The rationale for the present study was that a mechanical approach to reducing left atrial pressure might be effective in HFPEF. METHODS: The REDUCe Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF) study was an open-label, single-arm, phase 1 study designed to assess the performance and safety of a transcatheter interatrial shunt device (IASD, Corvia Medical, Tewkesbury, MA, USA) in patients older than 40 years of age with symptoms of HFPEF despite pharmacological therapy, left ventricular ejection fraction higher than 40%, and a raised pulmonary capillary wedge pressure at rest (>15 mm Hg) or during exercise (>25 mm Hg). The study was done at 21 centres (all departments of cardiology in the UK, Netherlands, Belgium, France, Germany, Austria, Denmark, Australia, and New Zealand). The co-primary endpoints were the safety and performance of the IASD at 6 months, together with measures of clinical efficacy, including functional capacity and clinical status, analysed per protocol. This study is registered with ClinicalTrials.gov, number NCT01913613. FINDINGS: Between Feb 8, 2014, and June 10, 2015, 68 eligible patients were entered into the study. IASD placement was successful in 64 patients and seemed to be safe and well tolerated; no patient had a peri-procedural or major adverse cardiac or cerebrovascular event or need for cardiac surgical intervention for device-related complications during 6 months of follow-up. At 6 months, 31 (52%) of 60 patients had a reduction in pulmonary capillary wedge pressure at rest, 34 (58%) of 59 had a lower pulmonary capillary wedge pressure during exertion, and 23 (39%) of 59 fulfilled both these criteria. Mean exercise pulmonary capillary wedge pressure was lower at 6 months than at baseline, both at 20 watts workload (mean 32 mm Hg [SD 8] at baseline vs 29 mm Hg [9] at 6 months, p=0·0124) and at peak exercise (34 mm Hg [8] vs 32 [8], p=0·0255), despite increased mean exercise duration (baseline vs 6 months: 7·3 min [SD 3·1] vs 8·2 min [3·4], p=0·03). Sustained device patency at 6 months was confirmed by left-to-right shunting (pulmonary/systemic flow ratio: 1·06 [SD 0·32] at baseline vs 1·27 [0·20] at 6 months, p=0·0004). INTERPRETATION: Implantation of an interatrial shunt device is feasible, seems to be safe, reduces left atrial pressure during exercise, and could be a new strategy for the management of HFPEF. The effectiveness of IASD compared with existing treatment for patients with HFPEF requires validation in a randomised controlled trial. FUNDING: Corvia Medical Inc.
650    _2
$a senioři $7 D000368
650    _2
$a srdeční katetrizace $7 D006328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x patofyziologie $x chirurgie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a implantace protézy $7 D019919
650    _2
$a tepový objem $7 D013318
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hayward, Chris $u St Vincent's Hospital, Sydney, NSW, Australia.
700    1_
$a Burkhoff, Dan $u Cardiology Department, Columbia University, New York, NY, USA.
700    1_
$a Silvestry, Frank E $u Hospital of the University of Pennsylvania, Philadelphia PA, USA.
700    1_
$a McKenzie, Scott $u The Prince Charles Hospital, Brisbane, Australia.
700    1_
$a Gustafsson, Finn $u Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
700    1_
$a Malek, Filip $u Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Van der Heyden, Jan $u St Antonius Ziekenhuis, Nieuwegein, Netherlands.
700    1_
$a Lang, Irene $u Allgemeines Krankenhaus Universitätskliniken, Vienna, Austria.
700    1_
$a Petrie, Mark C $u Golden Jubilee National Hospital, Glasgow, Scotland, UK.
700    1_
$a Cleland, John G F $u National Heart & Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK.
700    1_
$a Leon, Martin $u Columbia University Medical Center, New York, NY, USA.
700    1_
$a Kaye, David M $u Alfred Hospital and Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia. Electronic address: david.kaye@bakeridi.edu.au.
700    1_
$a ,
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 387, č. 10025 (2016), s. 1298-304
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27025436 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160727120618 $b ABA008
999    __
$a ok $b bmc $g 1154658 $s 944516
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 387 $c 10025 $d 1298-304 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace